Trial · NCT07424040
The Efficacy and Safety of Infliximab Combination With Azathioprine in Crohn's Disease in Children
NCT07424040, Not applicable, Not yet recruiting, The Children's Hospital of Zhejiang University School of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Efficacy and Safety of Infliximab Combination With Azathioprine in Crohn's Disease in Children. Trials, record NCT07424040. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07424040
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Efficacy and Safety of Infliximab Combination With Azathioprine in Crohn's Disease in Children
- NCT number
- NCT07424040
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 154 participants, estimated
- Lead sponsor
- The Children's Hospital of Zhejiang University School of Medicine
- Conditions
- Crohn's Diseases, Crohn's Disease in Pediatric Patient
- Interventions
- Infliximab combined with azathioprine therapy, Infliximab monotherapy
- First posted
- 2026-02-20
- Last updated
- 2026-02-20
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The clinical remission rates（(Pediatric Crohn's Disease Activity Index）in the 14th week and the 54th week | the 14th week and the 54th week | The clinical remission rateS of the children was evaluated using the PCDAI (Pediatric Crohn's Disease Activity Index). PCDAI\<10 was considered as clinical remission. |
| Secondary | Comparison of adverse reactions between the two treatment regimens within 54 weeks | within 54 weeks | Adverse reactions include infections, tumors, liver and kidney function impairments, myocardial damage, and bone marrow transplantation, etc Compare the incidence rates of adverse reactions between the two groups。 |
| Secondary | The mucosal healing rates （Simple Endoscopic Score for Crohn's Disease）in the 14th week and the 54th week | the 14th week and the 54th week | The SES-CD（Simple Endoscopic Score for Crohn's Disease）obtained under colonoscopy was used to evaluate the condition of mucosal healing. SES-CD\<3 was defined as mucosal healing. |
| Secondary | Patient-reported outcomes（PRO2） for the 14th week and the 54th week | the 14th week and the 54th week | The patient-reported outcomes for Crohn's disease use standardized assessment tools, namely the PRO2 scale, which includes two core symptoms: "abdominal pain" and "frequency of defecation". The minimum and maximum values of the PRO2 scale are 0 and above 30 respectively. Higher scores mean a worse outcome. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 37004887 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07424040
GET https://conductscience.org/api/trials/v1/NCT07424040/registered